The Honorable Susan Collins  
United States Senate  
413 Dirksen Senate Office Building  
Washington, D.C. 20515

The Honorable Edward Markey  
United States Senate  
255 Russell Senate Office Building  
Washington, D.C. 20515

The Honorable Mark Warner  
United States Senate  
703 Hart Senate Office Building  
Washington, D.C. 20515

The Honorable Shelley Moore Capito  
United States Senate  
172 Russell Senate Office Building  
Washington, D.C. 20515

The Honorable Jerry Moran  
United States Senate  
521 Dirksen Senate Office Building  
Washington, D.C. 20515

The Honorable Robert Menendez  
United States Senate  
528 Hart Senate Office Building  
Washington, D.C. 20515

May 12, 2022

Dear Senators Collins, Markey, Warner, Capito, Moran, and Menendez:

On behalf of the Alzheimer’s Association and the Alzheimer’s Impact Movement (AIM), including our nationwide network of advocates, thank you for your continued leadership on issues and legislation important to Americans living with Alzheimer’s and other dementia, and to their caregivers. The Alzheimer’s Association and AIM write today to strongly support the Alzheimer’s Accountability and Investment Act, S. 4202, which would continue the requirement for NIH to submit a Professional Judgment Budget (PJB) to Congress, among other provisions.

The burden of Alzheimer’s on individuals and families continues to grow. Today, more than 6 million Americans aged 65 and older are living with Alzheimer’s dementia and by mid-century, this number is expected to nearly double. Total payments for all individuals living with this disease are estimated at $321 billion (not including unpaid caregiving). Medicare and Medicaid are expected to cover $206 billion, or 64 percent of the total health care and long-term care payments for people with Alzheimer’s or other dementias. Total payments for health care costs, including hospice care, for people with Alzheimer’s and other dementias are projected to increase to nearly $1 trillion by 2050. These mounting costs threaten to bankrupt families, businesses, and our health care system. Unfortunately, our work is only growing more urgent.

The Alzheimer’s Accountability Act has allowed Congress to hear directly from the scientists at the NIH on how much research funding is needed to fully pursue scientific opportunities to prevent and effectively treat Alzheimer’s. The Alzheimer’s Accountability and Investment Act would continue the requirement for NIH to submit a professional judgment budget to Congress describing the annual funds needed to make progress in the fight against Alzheimer’s disease.

The Alzheimer’s Association and AIM deeply appreciate your continued leadership on behalf of all Americans living with Alzheimer’s and other dementia. If you have any questions about this or any other legislation, please contact Rachel Conant, Vice President of Federal Affairs, at reconant@alz-aim.org or at 202.638.7121.

Sincerely,
Robert Egge
Chief Public Policy Officer, Alzheimer’s Association
Executive Director, Alzheimer’s Impact Movement